Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes

Cardiovascular Drugs and Therapy

Volumn 31, Issue 5-6, 2017, Pages 545-549

  Kristensen, Søren L ^a,b   Jhund, Pardeep S ^a   Lee, Matthew M Y ^a   Køber, Lars ^b   Solomon, Scott D ^c   Granger, Christopher B ^d   Yusuf, Salim ^e   Pfeffer, Marc A ^c   Swedberg, Karl ^f,g   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Diabetes; Dysglycemia; Heart failure; Heart failure and preserved ejection fraction; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIGOXIN; DIURETIC AGENT; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CANADA; CAUSE OF DEATH; CLINICAL OUTCOME; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSGLYCEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; AGED; BLOOD; COMORBIDITY; HEART STROKE VOLUME; IMPAIRED GLUCOSE TOLERANCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; COMORBIDITY; DIABETES MELLITUS; FEMALE; GLYCATED HEMOGLOBIN A; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDIABETIC STATE; PREVALENCE; PROPORTIONAL HAZARDS MODELS; STROKE VOLUME;

EID: 85029799839     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-017-6754-x     Document Type: Article

References (15)

1. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668–73.
2. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996–1002.
3. Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007;115:1371–5.
4. Targher G, Dauriz M, Laroche C, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:54–65.
5. MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–85.
6. Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008;168:1699–704.
7. Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016;9:e002560.
8. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–66.
9. Authors/Task Force M, Rydén L, Grant PJ, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–87.
10. Dauriz M, Targher G, Temporelli PL, et al. Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc. 2017;6:e005156.
11. Centers for Disease Control and Prevention. National diabetes statistics report, 2017. U. S. Department of Health and Human Services; 2017.
12. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30:527–32.
13. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJ, Oliver MF. Insulin resistance in chronic heart failure. Eur Heart J. 1994;15:1528–32.
14. Swan JW, Walton C, Godsland IF. Assessment of insulin sensitivity in man: a comparison of minimal model- and euglycaemic clamp-derived measures in health and heart failure. Clin Sci. 1994;86:317–22.
15. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.